Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout

NCT01927198 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.

NCT NCT01927198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01927198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout
Lead sponsor
Ardea Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
July 31, 2014
Enrollment
172 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

gout